Kazia治疗机构筹集了4 650万美元,用于推进癌症药物试验,将其现金跑道延长到2028年。 Kazia Therapeutics raised $46.5 million to advance cancer drug trials, extending its cash runway to 2028.

Kazia Therapeutics 宣布进行一项5000万美元的私募，筹集4650万美元净收益，预计于2025年12月3日完成交易。 Kazia Therapeutics announced a $50 million private placement raising $46.5 million in net proceeds, set to close December 3, 2025. 这些资金将用于推进其主要候选药物paxalisib在脑癌和晚期乳腺癌中的临床试验,支持其PD-L1降解剂计划,并支付一般费用,延长公司的现金运行路径到2028年下半年. The funds will advance clinical trials for its lead drug candidate paxalisib in brain and advanced breast cancers, support its PD-L1 degrader program, and cover general expenses, extending the company’s cash runway into the second half of 2028. 股价在新闻后上升了10.5%至10.11美元,分析家预测有104%的上扬潜力。 The stock rose 10.5% to $10.11 following the news, with analysts projecting a potential 104% upside.